Shares in Britain’s largest drugmaker, AstraZeneca (LSE: AZN), have surged to a multi-month high following better-than-expected financial results for the first quarter of 2024.
The result will lend support to shareholders who recently approved a bumper new £18.7 million ($24 million) pay package for boss Sir Pascal Soriot, despite objections from some investors.
Total revenue was up 19% to $12.7 billion, driven by an 18% increase in sales and continued growth in alliance revenues from partnered medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze